These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 20400987)

  • 1. Long-term outcomes after hematopoietic SCT for adult T-cell leukemia/lymphoma: results of prospective trials.
    Choi I; Tanosaki R; Uike N; Utsunomiya A; Tomonaga M; Harada M; Yamanaka T; Kannagi M; Okamura J;
    Bone Marrow Transplant; 2011 Jan; 46(1):116-8. PubMed ID: 20400987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allogeneic hematopoietic stem cell transplantation using reduced-intensity conditioning for adult T cell leukemia/lymphoma: impact of antithymocyte globulin on clinical outcome.
    Tanosaki R; Uike N; Utsunomiya A; Saburi Y; Masuda M; Tomonaga M; Eto T; Hidaka M; Harada M; Choi I; Yamanaka T; Kannagi M; Matsuoka M; Okamura J
    Biol Blood Marrow Transplant; 2008 Jun; 14(6):702-8. PubMed ID: 18489996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Small number of HTLV-1-positive cells frequently remains during complete remission after allogeneic hematopoietic stem cell transplantation that are heterogeneous in origin among cases with adult T-cell leukemia/lymphoma.
    Yamasaki R; Miyazaki Y; Moriuchi Y; Tsutsumi C; Fukushima T; Yoshida S; Taguchi J; Inoue Y; Matsuo E; Imaizumi Y; Imanishi D; Fujimoto T; Tsushima H; Honda S; Hata T; Tsukasaki K; Tomonaga M
    Leukemia; 2007 Jun; 21(6):1212-7. PubMed ID: 17410191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
    Valcárcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Piñana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simón JA; Sierra J
    J Clin Oncol; 2008 Feb; 26(4):577-84. PubMed ID: 18086801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outpatient reduced-intensity allogeneic stem cell transplantation for patients with refractory or relapsed lymphomas compared with autologous stem cell transplantation using a simplified method.
    Gutiérrez-Aguirre CH; Ruiz-Argüelles G; Cantú-Rodríguez OG; González-Llano O; Jaime-Pérez JC; García-Rodríguez F; López-Otero A; Herrera-Garza JL; Gómez-Almaguer D
    Ann Hematol; 2010 Oct; 89(10):1045-52. PubMed ID: 20490794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Adult T cell leukemia/lymphoma (ATL)].
    Tanosaki R
    Nihon Rinsho; 2003 Sep; 61(9):1592-5. PubMed ID: 14515729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allogeneic bone marrow transplantation from unrelated human T-cell leukemia virus-I-negative donors for adult T-cell leukemia/lymphoma: retrospective analysis of data from the Japan Marrow Donor Program.
    Kato K; Kanda Y; Eto T; Muta T; Gondo H; Taniguchi S; Shibuya T; Utsunomiya A; Kawase T; Kato S; Morishima Y; Kodera Y; Harada M;
    Biol Blood Marrow Transplant; 2007 Jan; 13(1):90-9. PubMed ID: 17222757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allogenic hematopoietic stem-cell transplantation with reduced-intensity conditioning in patients with refractory and recurrent multiple myeloma: long-term follow-up.
    Shimoni A; Hardan I; Ayuk F; Schilling G; Atanackovic D; Zeller W; Yerushalmi R; Zander AR; Kroger N; Nagler A
    Cancer; 2010 Aug; 116(15):3621-30. PubMed ID: 20564132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved outcome of adult T cell leukemia/lymphoma with allogeneic hematopoietic stem cell transplantation.
    Utsunomiya A; Miyazaki Y; Takatsuka Y; Hanada S; Uozumi K; Yashiki S; Tara M; Kawano F; Saburi Y; Kikuchi H; Hara M; Sao H; Morishima Y; Kodera Y; Sonoda S; Tomonaga M
    Bone Marrow Transplant; 2001 Jan; 27(1):15-20. PubMed ID: 11244433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bone marrow transplantation from unrelated donors for patients with adult T-cell leukaemia/lymphoma.
    Nakase K; Hara M; Kozuka T; Tanimoto K; Nawa Y
    Bone Marrow Transplant; 2006 Jan; 37(1):41-4. PubMed ID: 16247419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New entity, definition and diagnostic criteria of cutaneous adult T-cell leukemia/lymphoma: human T-lymphotropic virus type 1 proviral DNA load can distinguish between cutaneous and smoldering types.
    Amano M; Kurokawa M; Ogata K; Itoh H; Kataoka H; Setoyama M
    J Dermatol; 2008 May; 35(5):270-5. PubMed ID: 18477226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Similar risks for chronic kidney disease in long-term survivors of myeloablative and reduced-intensity allogeneic hematopoietic cell transplantation.
    Al-Hazzouri A; Cao Q; Burns LJ; Weisdorf DJ; Majhail NS
    Biol Blood Marrow Transplant; 2008 Jun; 14(6):658-63. PubMed ID: 18489991
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinicopathological features of cutaneous lesions of adult T-cell leukaemia/ lymphoma.
    Yamaguchi T; Ohshima K; Karube K; Tutiya T; Kawano R; Suefuji H; Shimizu A; Nakayama J; Suzumiya J; Moroi Y; Urabe K; Furue M; Koga T; Kikuchi M
    Br J Dermatol; 2005 Jan; 152(1):76-81. PubMed ID: 15656804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of adult T-cell leukemia/lymphoma: past, present, and future.
    Ishitsuka K; Tamura K
    Eur J Haematol; 2008 Mar; 80(3):185-96. PubMed ID: 18081707
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High antileukemic efficacy of an intermediate intensity conditioning regimen for allogeneic stem cell transplantation in patients with high-risk acute myeloid leukemia in first complete remission.
    Schmid C; Schleuning M; Hentrich M; Markl GE; Gerbitz A; Tischer J; Ledderose G; Oruzio D; Hiddemann W; Kolb HJ
    Bone Marrow Transplant; 2008 Apr; 41(8):721-7. PubMed ID: 18176613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduced-intensity conditioned allogeneic haematopoietic stem cell transplantation results in durable disease-free and overall survival in patients with poor prognosis myeloid and lymphoid malignancies: eighty-month follow-up.
    Patil S; Spencer A; Schwarer A; Lewis I; Hertzberg M; Avery S; Wei A; Noutsos T; Paul E; Taouk Y; Muirhead J
    Bone Marrow Transplant; 2010 Jul; 45(7):1154-60. PubMed ID: 19898502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conventional versus reduced-intensity conditioning regimen for allogeneic stem cell transplantation in patients with hematological malignancies.
    Valcárcel D; Martino R; Sureda A; Canals C; Altés A; Briones J; Sanz MA; Parody R; Constans M; Villela SL; Brunet S; Sierra J
    Eur J Haematol; 2005 Feb; 74(2):144-51. PubMed ID: 15654906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells.
    Corradini P; Dodero A; Zallio F; Caracciolo D; Casini M; Bregni M; Narni F; Patriarca F; Boccadoro M; Benedetti F; Rambaldi A; Gianni AM; Tarella C
    J Clin Oncol; 2004 Jun; 22(11):2172-6. PubMed ID: 15169805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low nonrelapse mortality and prolonged long-term survival after reduced-intensity allogeneic stem cell transplantation for relapsed or refractory diffuse large B cell lymphoma: report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire.
    Sirvent A; Dhedin N; Michallet M; Mounier N; Faucher C; Yakoub-Agha I; Mohty M; Robin M; Tabrizi R; Clement L; Bilger K; Larosa F; Contentin N; Huyn A; François S; Bulabois CE; Ceballos P; Bourrhis JH; Buzyn A; Cornillon J; Guillerm G; de Revel T; Bay JO; Guilhot F; Milpied N
    Biol Blood Marrow Transplant; 2010 Jan; 16(1):78-85. PubMed ID: 19744569
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcome following Reduced-Intensity Allogeneic Stem Cell Transplantation (RIC AlloSCT) for relapsed and refractory mantle cell lymphoma (MCL): a study of the British Society for Blood and Marrow Transplantation.
    Cook G; Smith GM; Kirkland K; Lee J; Pearce R; Thomson K; Morris E; Orchard K; Rule S; Russell N; Craddock C; Marks DI;
    Biol Blood Marrow Transplant; 2010 Oct; 16(10):1419-27. PubMed ID: 20399879
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.